PMID- 18803074
OWN - NLM
STAT- MEDLINE
DCOM- 20090113
LR  - 20151119
IS  - 1748-2941 (Print)
IS  - 1748-2941 (Linking)
VI  - 10
IP  - 3
DP  - 2008
TI  - Clinical results of drug eluting stents compared to bare metal stents for 
      patients with ST elevation acute myocardial infarction.
PG  - 167-72
LID - 10.1080/17482940802360717 [doi]
AB  - OBJECTIVE: To investigate the clinical outcomes in patients with ST segment 
      elevation acute myocardial infarction (STEMI) treated with drug eluting stents 
      (DES) versus a matched control group of patients with STEMI treated with bare 
      metal stents (BMS). METHODS: This registry included 122 patients with STEMI 
      undergoing primary coronary angioplasty with DES implantation at our institution. 
      The control group consisted of 506 patients implanted with BMS, who were matched 
      for age, infarct location, and diabetic status. The incidences of major adverse 
      cardiac events (MACE) including target vessel/lesion revascularization (TVR/TLR) 
      and stent thrombosis were assessed up to 12 months. RESULTS: Twelve months follow 
      up showed a non-significant trend towards reduced deaths (3.3% versus 7.1%, 
      P=0.1), significantly reduced recurrent MI (0.0% versus 6.1%, P=0.02), TVR (5.7% 
      versus 15.2%, P=0.006) and TLR (2.5% versus 14.0%, P=0.004) events in the DES 
      group as compared to BMS group. The composite incidences of MACE at 12 months 
      follow-up was lower in the DES group (11.5%) as compared to the BMS group (21.3%, 
      P=0.01). CONCLUSION: According to our experiences, the use of DES in STEMI is 
      safe and effective as compared to BMS. DES was effective in reducing the 
      incidence of restenosis outcomes and overall adverse cardiac events up to 12 
      months.
FAU - Kornowski, R
AU  - Kornowski R
AD  - Cardiology Department, Rabin Medical Center, Petah-Tikva, The 'Sackler' Faculty 
      of Medicine, Tel-Aviv University, Israel. rkornowski@clalit.org.il
FAU - Vaknin-Assa, H
AU  - Vaknin-Assa H
FAU - Lev, E
AU  - Lev E
FAU - Ben-Dor, I
AU  - Ben-Dor I
FAU - Teplitsky, I
AU  - Teplitsky I
FAU - Rechavia, E
AU  - Rechavia E
FAU - Brosh, D
AU  - Brosh D
FAU - Fuchs, S
AU  - Fuchs S
FAU - Assali, A
AU  - Assali A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acute Card Care
JT  - Acute cardiac care
JID - 101276603
RN  - 0 (Immunosuppressive Agents)
RN  - H4GXR80IZE (zotarolimus)
RN  - P88XT4IS4D (Paclitaxel)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*therapy
MH  - Paclitaxel/administration & dosage
MH  - Registries
MH  - Retrospective Studies
MH  - Sirolimus/administration & dosage/analogs & derivatives
MH  - *Stents
EDAT- 2008/09/23 09:00
MHDA- 2009/01/14 09:00
CRDT- 2008/09/23 09:00
PHST- 2008/09/23 09:00 [pubmed]
PHST- 2009/01/14 09:00 [medline]
PHST- 2008/09/23 09:00 [entrez]
AID - 902579717 [pii]
AID - 10.1080/17482940802360717 [doi]
PST - ppublish
SO  - Acute Card Care. 2008;10(3):167-72. doi: 10.1080/17482940802360717.